Using CAR-T cell immunotherapy to target glioblastomas

December 14, 2016 | by Denise Heady

Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine’s biggest challenges: brain cancer. A clinical trial using patients’ own modified T cells to fight advanced brain tumors is currently being conducted.

One of but a few centers in the United States offering human studies in chimeric antigen receptor or CAR-T cell therapy, City of Hope is the only center investigating CAR-T cells in injection form administered directly to brain tumors. In this first-in-humans study, patients with advanced brain tumors will receive injections – directly at the tumor site and through the ventricular system – of immune cells genetically modified to recognize certain markers on cancer cells.

 

Behnam Badie Behnam Badie, M.D.

 

“The data from our preclinical studies makes us confident that this treatment has the potential to be very powerful and last longer than previous attempts at immunotherapy for brain cancer,” said Behnam Badie, M.D., chief of neurosurgery at City of Hope. “This could take the treatment of brain tumors to the next level, and open up a new avenue of treatment to patients who badly need it.”

The safety trial will evaluate the therapy in patients with inoperable glioblastomas and advanced gliomas and in those who have had their tumors surgically removed. The goal is to determine a safe therapeutic dose.

City of Hope has been offering CAR-T cell immunotherapy in clinical trials for several blood cancers. This trial will extend the exciting therapeutic approach to the fight against solid tumors.

T cells are cells in the immune system that recognize threats to the body, then mount an attack. Because cancer can hide from the immune system, CAR-T cell therapy modifies a patient’s T cells to recognize cancer cells. First, a sample of a patient’s T cells are extracted, then genetically modified to recognize receptors on cancer cells.

 

Christine Brown Bio Portrait Christine Brown, Ph.D.

 

This City of Hope trial is using a type of T cell known as memory T cells, meaning they replicate in the body and “remember” diseases they’ve fought previously. These memory cells give rise to “soldier” T cells that fight disease. The hope is that the immune system will mount an attack on the existing cancer – then do the same should the cancer recur.

The CAR-T cell research is overseen by Christine Brown, Ph.D., Heritage Provider Network Professor in Immunotherapy and associate director of the T Cell Therapeutics Research Laboratory, Stephen J. Forman, M.D., Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, and Badie, director of the Brain Tumor Program.

 

Stephen J. Forman Stephen J. Forman, M.D.

 

“CAR-T cell therapy has significant potential to fight not just blood and bone marrow cancers, but a wide range of diseases for which patients need better treatment,” Forman said. “City of Hope is committed to maximizing the potential of this revolutionary therapy for the sake of patients here and around the world.”

The research is being funded through grants from the California Institute of Regenerative Medicine and the Gateway for Cancer Research Foundation.

****

Physicians: If you are a physician and wish to refer a patient for enrollment, please email us at [email protected] or call 626-471-9393.

Patients: If you are a patient interested in learning more about our clinical trials, please email [email protected] or call 626-471-9393.

You can learn more about this clinical trial online at ClinicalTrials.gov.

Back To Top

Search Blogs